NAGIOS: RODERIC FUNCIONANDO

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

dc.contributor.author	Pajares, Bella	es_ES
dc.contributor.author	Pollán, Marina	es_ES
dc.contributor.author	Martín, Miguel	es_ES
dc.contributor.author	Mackey, John R	es_ES
dc.contributor.author	Lluch Hernández, Ana	es_ES
dc.contributor.author	Gavilá Gregori, Joaquín	es_ES
dc.contributor.author	Vogel, Charles	es_ES
dc.contributor.author	Ruiz-Borrego, Manuel	es_ES
dc.contributor.author	Calvo, Lourdes	es_ES
dc.contributor.author	Pienkowski, Tadeusz	es_ES
dc.contributor.author	Rodríguez-Lescure, Álvaro	es_ES
dc.contributor.author	Seguí, Miguel Angel	es_ES
dc.contributor.author	Tredan, Olivier	es_ES
dc.contributor.author	Antón, Antonio	es_ES
dc.contributor.author	Ramos, Manuel	es_ES
dc.contributor.author	Cámara, María del Carmen	es_ES
dc.contributor.author	Rodríguez-Martín, César	es_ES
dc.contributor.author	Carrasco, Eva	es_ES
dc.contributor.author	Alba, Emilio	es_ES
dc.date.accessioned	2015-06-19T07:47:44Z
dc.date.available	2015-06-19T07:47:44Z
dc.date.issued	2013	es_ES
dc.identifier.citation	Breast Cancer Research : BCR Vol. 15 Issue 6: pp. R105-R105	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44500
dc.description.abstract	IntroductionObesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification.MethodsWe performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003–02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of such prognostic effects by subtype.ResultsMultivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses to that of patients with a BMI < 25 (reference group) in terms of recurrence (Hazard Ratio [HR] = 1.08, 95% Confidence Interval [CI] = 0.90 to 1.30), BCM (HR = 1.02, 0.81 to 1.29), and OM (HR = 0.97, 0.78 to 1.19). Patients with severe obesity (BMI ≥ 35) had a significantly increased risk of recurrence (HR = 1.26, 1.00 to 1.59, P = 0.048), BCM (HR = 1.32, 1.00 to 1.74, P = 0.050), and OM (HR = 1.35, 1.06 to 1.71, P = 0.016) compared to our reference group. The prognostic effect of severe obesity did not vary by subtype.ConclusionsSeverely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes.	es_ES
dc.title	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.1186/bcr3572	es_ES
dc.identifier.idgrec	094779	es_ES